Walvax Biotechnology Co., Ltd.
300142
Peringkat dalam Saham
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Harga Saham
$1.87
Kapitalisasi Pasar
$2.98B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
14.73%
Negara
CN
Perdagangan Walvax Biotechnology Co., Ltd. (300142)
Kategori
Healthcare
Laba untuk Walvax Biotechnology Co., Ltd. (300142)
Laba pada Jun 2026 TTM: $33.43M
Menurut laporan keuangan terbaru dari Walvax Biotechnology Co., Ltd., laba saat ini perusahaan adalah $33.43M. Pada tahun 2024, perusahaan memperoleh laba sebesar $25.28M, penurunan dibandingkan dengan laba tahun 2023 sebesar $84.62M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Walvax Biotechnology Co., Ltd. dari 2007 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $33.43M | 40.82% |
| 2025 | $23.74M | -6.07% |
| 2024 | $25.28M | -70.13% |
| 2023 | $84.62M | -45.47% |
| 2022 | $155.19M | 39.13% |
| 2021 | $111.54M | -46.94% |
| 2020 | $210.22M | 537.94% |
| 2019 | $32.95M | -80.85% |
| 2018 | $172.06M | -294.12% |
| 2017 | $-88.63M | -1,874.21% |
| 2016 | $5.00M | -103.67% |
| 2015 | $-136.24M | -711.67% |
| 2014 | $22.27M | 1,211.52% |
| 2013 | $1.70M | -96.04% |
| 2012 | $42.89M | 9.96% |
| 2011 | $39.01M | 40.55% |
| 2010 | $27.75M | 101.15% |
| 2009 | $13.80M | 117.38% |
| 2008 | $6.35M | 390.06% |
| 2007 | $1.30M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $3.62B | 10,720.80% |
DE
|
|
| $3.40B | 10,084.09% |
DE
|
|
| $1.72B | 5,055.23% |
JP
|
|
| $930.30M | 2,682.47% |
CH
|
|
| $1.69B | 4,962.63% |
IN
|
